Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 4—April 2004
Research

Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs

Emily L.C. Tan*, Eng Eong Ooi†, Chin-Yo Lin*, Hwee Cheng Tan†, Ai Ee Ling‡, Bing Lim*, and Lawrence W. Stanton*Comments to Author 
Author affiliations: *Genome Institute of Singapore, Singapore; †National Environmental Agency, Singapore; ‡Singapore General Hospital, Singapore

Main Article

Table 2

Examples of inhibitory concentrations of antiviral drugs against selected virusesa

Compound IC50 Virus
Foscavir
50–800 μM
Cytomegalovirus

5–443 μM
Herpes simplex mutants
Acyclovir
0.01–13.5 μg/ml
Herpes smplex virus and varicella-zoster virus
Cymevene
0.02–3.48 μg/mL
Laboratory strains or clinical isolates of cytomegalovirus
Ribavirin
1–25 μg/mL
Influenza

25–100 μg/mL
HIV and other retroviruses

3.2–50 μg/ml (MIC)
Herpes and poxviruses suppression
Lamivudine
0.0006–0.034 μg/mL
HIV
Zidovudine
0.003–0.013 μg/mL
HIV
Fortovase
1–30 nM
HIV
Viracept
7–196 nM (EC95)
HIV
Crixivan
25–100 nM
HIV
Relenza
0.005–16 μM
Influenza virus
Tamiflu
0.0008 μM–>35 μM
Influenza virus
Amantadine 0.1–25 (ED50) Influenza virus

aIC50, 50% inhibitory concentration; EC95, 95% effective concentration; ED50, 50% effective dose.

Main Article

Page created: February 09, 2011
Page updated: February 09, 2011
Page reviewed: February 09, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external